Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31379599 | 1.00 | AOC3 (0.51) | AOC3MTNR1AMTNR1BTAAR1BCHE | |
| SCHEMBL7331644 | 0.80 | MTNR1A (0.60) | AOC3MTNR1AMTNR1BTAAR1CASP3 | |
| SCHEMBL30800373 | 0.80 | MTNR1A (0.60) | AOC3MTNR1AMTNR1BTAAR1CASP3 | |
| SCHEMBL7450385 | 0.80 | KMT2A (0.66) | BCHEACHECHRM2CHRM1MEN1 | |
| SCHEMBL13227198 | 0.79 | CDYL (0.52) | MTNR1AMTNR1B | |
| SCHEMBL29590071 | 0.78 | LMNA (0.59) | MTNR1AMTNR1BTAAR1 | |
| SCHEMBL30365164 | 0.78 | MTNR1A (0.63) | MTNR1AMTNR1BTAAR1KMT2ACASP3 | |
| SCHEMBL362209 | 0.78 | LMNA (0.59) | MTNR1AMTNR1BTAAR1 | |
| SCHEMBL266525 | 0.78 | MTNR1A (0.63) | MTNR1AMTNR1BTAAR1KMT2ACASP3 | |
| SCHEMBL2437293 | 0.77 | TAAR1 (0.59) | AOC3MTNR1AMTNR1BTAAR1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2994128-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-9765089-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765089-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160185799-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-06-30 | — | — | US | disclosed |
| US-20160185799-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185799-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | AOC3 369/4885MTNR1A 4218/4885MTNR1B 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.